149 related articles for article (PubMed ID: 30661456)
21. Efficacy of EZH2 inhibitory drugs in human papillomavirus-positive and human papillomavirus-negative oropharyngeal squamous cell carcinomas.
Lindsay CD; Kostiuk MA; Harris J; O'Connell DA; Seikaly H; Biron VL
Clin Epigenetics; 2017; 9():95. PubMed ID: 28878842
[TBL] [Abstract][Full Text] [Related]
22. H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells.
Tripathy MK; McManamy ME; Burch BD; Archin NM; Margolis DM
J Virol; 2015 Aug; 89(16):8392-405. PubMed ID: 26041287
[TBL] [Abstract][Full Text] [Related]
23. Enhancer of Zeste Homolog 2 (EZH2) Contributes to Rod Photoreceptor Death Process in Several Forms of Retinal Degeneration and Its Activity Can Serve as a Biomarker for Therapy Efficacy.
Mbefo M; Berger A; Schouwey K; Gérard X; Kostic C; Beryozkin A; Sharon D; Dolfuss H; Munier F; Tran HV; van Lohuizen M; Beltran WA; Arsenijevic Y
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502238
[TBL] [Abstract][Full Text] [Related]
24. UTX/KDM6A Loss Enhances the Malignant Phenotype of Multiple Myeloma and Sensitizes Cells to EZH2 inhibition.
Ezponda T; Dupéré-Richer D; Will CM; Small EC; Varghese N; Patel T; Nabet B; Popovic R; Oyer J; Bulic M; Zheng Y; Huang X; Shah MY; Maji S; Riva A; Occhionorelli M; Tonon G; Kelleher N; Keats J; Licht JD
Cell Rep; 2017 Oct; 21(3):628-640. PubMed ID: 29045832
[TBL] [Abstract][Full Text] [Related]
25. Role of EZH2-mediated H3K27me3 in placental ADAM12-S expression: implications for fetoplacental growth.
Zhu YN; Gan XW; Pan F; Ni XT; Myatt L; Wang WS; Sun K
BMC Med; 2022 May; 20(1):189. PubMed ID: 35610640
[TBL] [Abstract][Full Text] [Related]
26. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.
Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L
Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841
[TBL] [Abstract][Full Text] [Related]
27. Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
Yang X; Li F; Konze KD; Meslamani J; Ma A; Brown PJ; Zhou MM; Arrowsmith CH; Kaniskan HÜ; Vedadi M; Jin J
J Med Chem; 2016 Aug; 59(16):7617-33. PubMed ID: 27468126
[TBL] [Abstract][Full Text] [Related]
28. Histone deacetylase inhibition modulates histone acetylation at gene promoter regions and affects genome-wide gene transcription in Schistosoma mansoni.
Anderson L; Gomes MR; daSilva LF; Pereira ADSA; Mourão MM; Romier C; Pierce R; Verjovski-Almeida S
PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005539. PubMed ID: 28406899
[TBL] [Abstract][Full Text] [Related]
29. Normal formation of a vertebrate body plan and loss of tissue maintenance in the absence of ezh2.
San B; Chrispijn ND; Wittkopp N; van Heeringen SJ; Lagendijk AK; Aben M; Bakkers J; Ketting RF; Kamminga LM
Sci Rep; 2016 May; 6():24658. PubMed ID: 27145952
[TBL] [Abstract][Full Text] [Related]
30. Dual Inhibition of EZH2 and EZH1 Sensitizes PRC2-Dependent Tumors to Proteasome Inhibition.
Rizq O; Mimura N; Oshima M; Saraya A; Koide S; Kato Y; Aoyama K; Nakajima-Takagi Y; Wang C; Chiba T; Ma A; Jin J; Iseki T; Nakaseko C; Iwama A
Clin Cancer Res; 2017 Aug; 23(16):4817-4830. PubMed ID: 28490465
[No Abstract] [Full Text] [Related]
31. BRCA1 and EZH2 cooperate in regulation of prostate cancer stem cell phenotype.
Gorodetska I; Lukiyanchuk V; Peitzsch C; Kozeretska I; Dubrovska A
Int J Cancer; 2019 Dec; 145(11):2974-2985. PubMed ID: 30968962
[TBL] [Abstract][Full Text] [Related]
32. Polycomb gene expression and histone H3 lysine 27 trimethylation changes during bovine preimplantation development.
Ross PJ; Ragina NP; Rodriguez RM; Iager AE; Siripattarapravat K; Lopez-Corrales N; Cibelli JB
Reproduction; 2008 Dec; 136(6):777-85. PubMed ID: 18784248
[TBL] [Abstract][Full Text] [Related]
33. EZH2 inhibition in multiple myeloma downregulates myeloma associated oncogenes and upregulates microRNAs with potential tumor suppressor functions.
Alzrigat M; Párraga AA; Agarwal P; Zureigat H; Österborg A; Nahi H; Ma A; Jin J; Nilsson K; Öberg F; Kalushkova A; Jernberg-Wiklund H
Oncotarget; 2017 Feb; 8(6):10213-10224. PubMed ID: 28052011
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of the methyltranferase EZH2 improves aortic performance in experimental thoracic aortic aneurysm.
Lino Cardenas CL; Kessinger CW; MacDonald C; Jassar AS; Isselbacher EM; Jaffer FA; Lindsay ME
JCI Insight; 2018 Mar; 3(5):. PubMed ID: 29515022
[TBL] [Abstract][Full Text] [Related]
35. EZH2 inhibits NK cell-mediated antitumor immunity by suppressing CXCL10 expression in an HDAC10-dependent manner.
Bugide S; Gupta R; Green MR; Wajapeyee N
Proc Natl Acad Sci U S A; 2021 Jul; 118(30):. PubMed ID: 34301901
[TBL] [Abstract][Full Text] [Related]
36. [Distributions of H3K27me3 and its modification enzymes in different tissues of mice].
Wang Y; Wang X; Zhang R; Zhang Z; Wang Y; Yang B; Wang G; Zhang X; Ma F; Xu H; Wu X; Zhang F; Li Q
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Nov; 33(11):1491-1497. PubMed ID: 29268852
[TBL] [Abstract][Full Text] [Related]
37. Wedelolactone Targets EZH2-mediated Histone H3K27 Methylation in Mantle Cell Lymphoma.
Romanchikova N; Trapencieris P
Anticancer Res; 2019 Aug; 39(8):4179-4184. PubMed ID: 31366503
[TBL] [Abstract][Full Text] [Related]
38. Three-dimensional culture sensitizes epithelial ovarian cancer cells to EZH2 methyltransferase inhibition.
Amatangelo MD; Garipov A; Li H; Conejo-Garcia JR; Speicher DW; Zhang R
Cell Cycle; 2013 Jul; 12(13):2113-9. PubMed ID: 23759589
[TBL] [Abstract][Full Text] [Related]
39. Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation.
Gannon OM; Merida de Long L; Endo-Munoz L; Hazar-Rethinam M; Saunders NA
Clin Cancer Res; 2013 Jan; 19(2):428-41. PubMed ID: 23186778
[TBL] [Abstract][Full Text] [Related]
40. Maternal Ezh1/2 deficiency in oocyte delays H3K27me2/3 restoration and impairs epiblast development responsible for embryonic sub-lethality in mouse.
Zhao Y; Bai D; Wu Y; Zhang D; Liu M; Tian Y; Lu J; Wang H; Gao S; Lu Z
Development; 2022 Aug; 149(15):. PubMed ID: 35796552
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]